<DOC>
	<DOCNO>NCT02823470</DOCNO>
	<brief_summary>The study evaluate impact smart adherence technology monitoring lumacaftor/ivacaftor ( LUM/IVA ) adherence rate among subject 16 year age old Cystic Fibrosis ( CF ) homozygous F508del Cystic Fibrosis Transmembrane Conductance Regulator ( CFTR ) mutation .</brief_summary>
	<brief_title>A Pilot Study Evaluate Use Smart Adherence Technology Measure Lumacaftor/Ivacaftor Adherence CF Subjects Homozygous F508del CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Subject ( legally appoint authorized representative ) sign date inform consent form ( ICF ) . Willing able comply schedule visit , treatment plan , study restriction , laboratory test , contraceptive guideline , study procedure . Confirmed diagnosis CF homozygous F508delCFTR mutation Forced Expiratory Volume one second/forced vital capacity ( FEV1 ) â‰¥40 % predict normal age , sex , height Presence moderate severe hepatic impairment ( ChildPugh Class B C ) Subjects currently receive invasive mechanical ventilation Known history alcohol drug abuse past year Clinically significant abnormal laboratory value screen Pregnant nursing female Female subject female partner male subject plan become pregnant Treatment Period within 90 day follow last dose study drug History solid organ hematological transplantation Ongoing prior participation investigational drug study within 30 day screen Current use commercial LUM/IVA combination therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>